The Department of Biochemistry - Faculty of Pharmacy has decided to hold the oral exam for the students of Semester (8) of the elective course (Tissue Metabolism) on Saturday, 5/25/2024. 2 pm before the Final exam.

In this work, Tamarindus indica (T. indica)-loaded crosslinked poly(methyl methacrylate) (PMMA)/cellulose acetate (CA)/poly(ethylene oxide) (PEO) electrospun nanofibers were designed and fabricated for wound healing applications. T. indica is a plant extract that possesses antidiabetic, antimicrobial, antioxidant, antimalarial and wound healing properties. T. indica leaves extract of different concentrations were blended with a tuned composition of a matrix comprised of PMMA (10 %), CA (2 %) and PEO (1.5 %), and were electrospun to form smooth, dense and continuous nanofibers as illustrated by SEM investigation. In vitro evaluation of T. indica-loaded nanofibers on normal human skin fibroblasts (HBF4) revealed a high compatibility and low cytotoxicity. T. indica-loaded nanofibers significantly increased the healing activity of scratched HBF4 cells, as compared to the free plant extract, and the healing activity was significantly enhanced upon increasing the plant extract concentration. Moreover, T. indica-loaded nanofibers demonstrated significant antimicrobial activity in vitro against the tested microbes. In vivo, nanofibers resulted in a superior wound healing efficiency compared to the control untreated animals. Hence, engineered nanofibers loaded with potent phytochemicals could be exploited as an effective biocompatible and eco-friendly antimicrobial biomaterials and wound healing composites.

Exploitation of nanocarriers provides a compartment for enclosing drugs to protect them from degradation and potentiate their therapeutic efficiency. In the current study, amitriptyline- and liraglutide-loaded proniosomes were constructed for management of diabetic neuropathy, a serious complication associated with diabetes, that triggers spontaneous pain in patients and results in impaired quality of life. The developed therapeutic proniosomes were extensively characterized via dynamic light scattering, scanning electron microscopy, transmission electron microscopy, and Fourier transform-infrared spectroscopy. High entrapment efficiency could be attained for both drugs in the proniosomes, and the reconstituted amitriptyline- and liraglutide-loaded niosomes possessed spherical morphology and particle sizes of 585.3 nm and 864.4 nm, respectively. In a diabetic neuropathy rat model, oral administration of the developed amitriptyline- and liraglutide-loaded proniosomes significantly controlled blood glucose levels, reduced neuropathic pain, oxidative stress and inflammatory markers, and improved histological structure of the sciatic nerve as compared to the oral and subcutaneous administration of amitriptyline and liraglutide, respectively. Loading of the tricyclic antidepressant amitriptyline and the antidiabetic peptide liraglutide into proniosomes resulted in exceptional control over hyperglycemia and neuropathic pain, and thus could provide an auspicious delivery system for management of neuropathic pain and control of blood glucose levels.

Novel biomass-derived carbon dots co-doped with nitrogen and sulfur were fabricated through facile and simple synthetic method from manufactured milk powder and methionine as precursors. The as-fabricated platform was used for ratiometric fluorescence sensing of Cu (II) and bisphosphonate drug risedronate sodium. The sensing platform is based on oxidation of o-phenylenediamine by Cu (II) to form 2, 3-diaminophenazine (oxidized product) with an emission peak at 557 nm. The resultant product quenched the fluorescence emission of as-fabricated carbon dots at 470 nm through Förster resonance energy transfer (FRET) and inner-filter effect (IFE). Upon addition of risedronate sodium, the formation of 2, 3-diaminophenazine was decreased as a result of Cu (II) chelation with risedronate sodium, recovering the fluorescence emission of carbon dots. The ratio of fluorescence at 470 nm and 557 nm was measured as a function of Cu (II) and risedronate sodium concentrations. The proposed sensing platform sensitively detected Cu (II) and risedronate sodium in the range of 0.01–55 μM and 5.02–883 µM with LODs (S/N = 3) of 0.003 μM and 1.48 µM, respectively. The sensing platform exhibited a good selectivity towards Cu (II) and risedronate sodium. The sensing system was used to determine Cu (II) and risedronate sodium in different sample matrices with recoveries % in the range of 99–103 % and 97.4–103.8 %, and RSDs % in the range of 1.5–3.0 % and 1.8–3.6 %, respectively.